Around one percent of people worldwide live with schizophrenia. This mental health issue poses major hurdles for successful care. Even with modern antipsychotics available, numerous individuals still deal with ongoing issues like thinking problems and side effects that reduce commitment to therapy. Our analysis gathers findings from work between 2020 and 2025 on fresh drug options, therapy sessions, and prompt action plans. The team scanned key resources including PubMed, PsycINFO, Embase, Web of Science, and Cochrane Library. They reviewed 130 trials with random assignment and 50 group follow-ups. Findings indicated that recent antipsychotics offered solid results with effect sizes at 0.55 using Hedges' g. Behavioral therapy aimed at cognition boosted daily performance notably at g equals 0.67. Other fresh methods like magnetic brain stimulation and simulated environments also held potential for easing hallucinations and mental fog. Yet obstacles persist for cases that resist standard care including frequent returns of symptoms and thinking lapses. This work stresses the value of more studies to shape custom care routines and strengthen early support systems for better results over time.

Schizophrenia Antipsychotics Cognitive Behavioral Therapy Transcranial Magnetic Stimulation Virtual Reality